196 related articles for article (PubMed ID: 33837665)
1. Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.
Castillo-Ecija H; Pascual-Pasto G; Perez-Jaume S; Resa-Pares C; Vila-Ubach M; Monterrubio C; Jimenez-Cabaco A; Baulenas-Farres M; Muñoz-Aznar O; Salvador N; Cuadrado-Vilanova M; Olaciregui NG; Balaguer-Lluna L; Burgueño V; Vicario FJ; Manzanares A; Castañeda A; Santa-Maria V; Cruz O; Celis V; Morales La Madrid A; Garraus M; Gorostegui M; Vancells M; Carrasco R; Krauel L; Torner F; Suñol M; Lavarino C; Mora J; Carcaboso AM
J Pathol Clin Res; 2021 Jul; 7(4):338-349. PubMed ID: 33837665
[TBL] [Abstract][Full Text] [Related]
2. Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.
Nanni P; Landuzzi L; Manara MC; Righi A; Nicoletti G; Cristalli C; Pasello M; Parra A; Carrabotta M; Ferracin M; Palladini A; Ianzano ML; Giusti V; Ruzzi F; Magnani M; Donati DM; Picci P; Lollini PL; Scotlandi K
Sci Rep; 2019 Aug; 9(1):12174. PubMed ID: 31434953
[TBL] [Abstract][Full Text] [Related]
3. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
[TBL] [Abstract][Full Text] [Related]
4. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.
Chen Y; Zhang R; Wang L; Correa AM; Pataer A; Xu Y; Zhang X; Ren C; Wu S; Meng QH; Fujimoto J; Jensen VB; Antonoff MB; Hofstetter WL; Mehran RJ; Pisimisis G; Rice DC; Sepesi B; Vaporciyan AA; Walsh GL; Swisher SG; Roth JA; Heymach JV; Fang B
Cancer; 2019 Nov; 125(21):3738-3748. PubMed ID: 31287557
[TBL] [Abstract][Full Text] [Related]
5. Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing.
Cornillie J; Wozniak A; Li H; Wang Y; Boeckx B; Gebreyohannes YK; Wellens J; Vanleeuw U; Hompes D; Stas M; Sinnaeve F; Wafa H; Lambrechts D; Debiec-Rychter M; Sciot R; Schöffski P
Mol Cancer Ther; 2019 Jun; 18(6):1168-1178. PubMed ID: 30962320
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of xenograft engraftment in patients with metastatic high-risk neuroblastoma.
Aschero R; Castillo-Ecija H; Baulenas-Farres M; Resa-Pares C; Jimenez-Cabaco A; Rodriguez E; Monterrubio C; Perez-Jaume S; Suñol M; Chantada GL; Lavarino C; Mora J; Carcaboso AM
Pediatr Blood Cancer; 2023 Jun; 70(6):e30318. PubMed ID: 36973999
[TBL] [Abstract][Full Text] [Related]
7. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers.
Moon HG; Oh K; Lee J; Lee M; Kim JY; Yoo TK; Seo MW; Park AK; Ryu HS; Jung EJ; Kim N; Jeong S; Han W; Lee DS; Noh DY
Breast Cancer Res Treat; 2015 Nov; 154(1):13-22. PubMed ID: 26438141
[TBL] [Abstract][Full Text] [Related]
9. Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.
Ju HY; Park M; Lee JA; Park HJ; Park SY; Kim JH; Kang HG; Yang HC; Park BK
Cancer Res Treat; 2022 Apr; 54(2):563-571. PubMed ID: 34126703
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer.
Chen Q; Wei T; Wang J; Zhang Q; Li J; Zhang J; Ni L; Wang Y; Bai X; Liang T
Pancreatology; 2020 Apr; 20(3):485-492. PubMed ID: 32113935
[TBL] [Abstract][Full Text] [Related]
11. Ewing Sarcoma PDX Models.
Surdez D; Landuzzi L; Scotlandi K; Manara MC
Methods Mol Biol; 2021; 2226():223-242. PubMed ID: 33326106
[TBL] [Abstract][Full Text] [Related]
12. Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma.
Pascual-Pasto G; Resa-Pares C; Castillo-Ecija H; Aschero R; Baulenas-Farres M; Vila-Ubach M; Burgueño V; Balaguer-Lluna L; Cuadrado-Vilanova M; Olaciregui NG; Martinez-Velasco N; Perez-Jaume S; de Alava E; Tirado OM; Lavarino C; Mora J; Carcaboso AM
Biochem Pharmacol; 2023 Feb; 208():115408. PubMed ID: 36603685
[TBL] [Abstract][Full Text] [Related]
13. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Yu PY; Gardner HL; Roberts R; Cam H; Hariharan S; Ren L; LeBlanc AK; Xiao H; Lin J; Guttridge DC; Mo X; Bennett CE; Coss CC; Ling Y; Phelps MA; Houghton P; London CA
PLoS One; 2017; 12(7):e0181885. PubMed ID: 28750090
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.
Mora J; Cruz CO; Parareda A; de Torres C
J Pediatr Hematol Oncol; 2009 Oct; 31(10):723-9. PubMed ID: 19727011
[TBL] [Abstract][Full Text] [Related]
15. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.
Harrison DJ; Gill JD; Roth ME; Zhang W; Teicher B; Erickson S; Gatto G; Kurmasheva RT; Houghton PJ; Smith MA; Kolb EA; Gorlick R
Pediatr Blood Cancer; 2020 Jun; 67(6):e28222. PubMed ID: 32207565
[TBL] [Abstract][Full Text] [Related]
16. SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas.
Pascual-Pasto G; Castillo-Ecija H; Unceta N; Aschero R; Resa-Pares C; Gómez-Caballero A; Vila-Ubach M; Muñoz-Aznar O; Suñol M; Burgueño V; Gomez-Gonzalez S; Sosnik A; Ibarra M; Schaiquevich P; de Álava E; Tirado OM; Mora J; Carcaboso AM
J Control Release; 2022 Feb; 342():81-92. PubMed ID: 34974029
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
Baruchel S; Pappo A; Krailo M; Baker KS; Wu B; Villaluna D; Lee-Scott M; Adamson PC; Blaney SM
Eur J Cancer; 2012 Mar; 48(4):579-85. PubMed ID: 22088484
[TBL] [Abstract][Full Text] [Related]
18. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment Neutrophil-to-Lymphocyte Ratio and Lymphocyte Recovery: Independent Prognostic Factors for Survival in Pediatric Sarcomas.
Vasquez L; León E; Beltran B; Maza I; Oscanoa M; Geronimo J
J Pediatr Hematol Oncol; 2017 Oct; 39(7):538-546. PubMed ID: 28697168
[TBL] [Abstract][Full Text] [Related]
20. Thioredoxin Reductase Inhibitor Suppresses the Local Progression of Rhabdomyosarcoma With PDX Models.
Kinoshita H; Kinoshita S; Kamoda H; Hagiwara Y; Ohtori S; Yonemoto T
Cancer Genomics Proteomics; 2024; 21(2):178-185. PubMed ID: 38423598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
